{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of confidence interval is not estimable due to insufficient events being observed at the time of the analysis.","groupId":"OG000","lowerLimit":"0.9","upperLimit":"NA","value":"14.8"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"115.0","value":"84.8"},{"comment":"Median and upper limit of confidence interval are not estimable due to insufficient events being observed at the time of the analysis.","groupId":"OG002","lowerLimit":"60.6","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of confidence interval is not estimable due to insufficient events being observed at the time of the analysis.","groupId":"OG003","lowerLimit":"1.5","upperLimit":"NA","value":"18.6"},{"comment":"Median and upper limit of confidence interval are not estimable due to insufficient events being observed at the time of the analysis.","groupId":"OG004","lowerLimit":"2.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with EBV+ PTLD following HCT who were R/R to rituximab received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following SOT who were R/R to rituximab and chemotherapy received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)"},{"description":"Participants with EBV+ following LMS received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"EBV+ LMS (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following HCT who were R/R to rituximab or rituximab naive received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)"},{"description":"Participants with EBV+ following viremia received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"EBV+ Viremia (EBV-CTLs Only)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Results from arms with \\<= 3 participants (as shown in the participant flow) are excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 251.1 months after Day 1 dose","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}